Superluminal Medicines pricing
No pricing page, rate card or unit of charge exists, which is expected for a company that licenses no software. The commercial disclosure that does exist is well structured. The August 2025 Eli Lilly collaboration is stated at up to $1.3 billion and broken into its components: upfront and near term payments, an equity investment, development and commercial milestones, and tiered royalties on net sales, with Lilly holding exclusive development and commercialization rights to compounds arising from the work.
How Superluminal Medicines pricing works
- Pricing model
- Negotiated collaboration. Revenue comes from pharmaceutical discovery partnerships paid through upfront and near term payments, equity investment, development and commercial milestones, and tiered royalties on net sales, with the partner taking exclusive rights to resulting compounds. The company also funds wholly owned programs it intends to develop itself. No software license, subscription or platform access is offered.
- Implementation
- Not published and structurally absent, since nothing is installed or licensed to a partner. The corresponding cost sits inside the collaboration and inside the company: Superluminal runs its own discovery operation and licenses its own third party software stack, and the Lilly agreement includes near term payments and an equity investment rather than an itemized service fee. Laboratory occupancy is another cost that never surfaces as a line item, since the company operates from its partner's incubator facility.
What is still missing is any individual amount, so the upfront, the equity and the milestone tranches are all unsized and $1.3 billion remains a ceiling that may never be reached. Equity funding is disclosed with leads and syndicates named: $33 million in seed in August 2023, $120 million in Series A in September 2024, and $60 million in Series B on 3 September 2026 led by BVF Partners, $213 million in total.
One entanglement belongs with any reading of these figures: Eli Lilly is an investor, the largest commercial partner, and the landlord, since the company's registered address is inside Lilly Gateway Labs.
Superluminal Medicines pricing against its alternatives
Published prices for Superluminal Medicines and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.
- SSuperluminal MedicinesNo published price
- NNabla BioNo published price
- AAntiverseNo published price
- PPostEraNo published price
- BBigHat BiosciencesNo published price
- NNumerion LabsNo published price
- EEnvedaNot applicable
- GGenesis Molecular AINo published price
- AAbsciNo published price
Superluminal Medicines pricing, answered
How much does Superluminal Medicines cost?
Superluminal Medicines does not publish a price. The commercial disclosure that does exist is well structured.
Does Superluminal Medicines charge an implementation fee?
Not published and structurally absent, since nothing is installed or licensed to a partner. The corresponding cost sits inside the collaboration and inside the company: Superluminal runs its own discovery operation and licenses its own third party software stack, and the Lilly agreement includes near term payments and an equity investment rather than an itemized service fee. Laboratory occupancy is another cost that never surfaces as a line item, since the company operates from its partner's incubator facility.